265 related articles for article (PubMed ID: 3154307)
1. Preclinical studies on angiotensin converting enzyme inhibitors.
Natoff IL
Cardiovasc Drugs Ther; 1987; 1(1):15-27. PubMed ID: 3154307
[TBL] [Abstract][Full Text] [Related]
2. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.
Unger T; Gohlke P
Am J Cardiol; 1990 May; 65(19):3I-10I. PubMed ID: 2159693
[TBL] [Abstract][Full Text] [Related]
3. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
Kolloch R; Offers E
Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
[No Abstract] [Full Text] [Related]
4. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
5. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.
Fujii M; Wada A; Ohnishi M; Tsutamoto T; Matsumoto T; Yamamoto T; Takayama T; Dohke T; Isono T; Eguchi Y; Horie M
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S346-9. PubMed ID: 15838317
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin system in hypertension: an update.
Brunner HR
Hosp Pract (Off Ed); 1990 Aug; 25(8):71-81. PubMed ID: 2116434
[TBL] [Abstract][Full Text] [Related]
7. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
8. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
Galvao M
Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
[TBL] [Abstract][Full Text] [Related]
9. [Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists].
Asmar R; Madonna O; Brisac AM; Benetos A; Laurent S
Therapie; 1998; 53(3):253-70. PubMed ID: 9773125
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Jorde UP; Vittorio T; Katz SD; Colombo PC; Latif F; Le Jemtel TH
Circulation; 2002 Aug; 106(9):1055-7. PubMed ID: 12196328
[TBL] [Abstract][Full Text] [Related]
11. [Chronic cardiac insufficiency. Treatment with angiotensin I converting enzyme inhibitors and angiotensin II receptor antagonists].
Juilliére Y; Berder V
Presse Med; 2000 Apr; 29(13):743-8. PubMed ID: 10797830
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors in heart failure.
Borek M; Charlap S; Frishman WH
Med Clin North Am; 1989 Mar; 73(2):315-38. PubMed ID: 2645479
[TBL] [Abstract][Full Text] [Related]
13. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
14. Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
Woie L; Dickstein K; Kaada B
Gen Pharmacol; 1987; 18(6):577-87. PubMed ID: 2822521
[TBL] [Abstract][Full Text] [Related]
15. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.
Kittleson M; Hurwitz S; Shah MR; Nohria A; Lewis E; Givertz M; Fang J; Jarcho J; Mudge G; Stevenson LW
J Am Coll Cardiol; 2003 Jun; 41(11):2029-35. PubMed ID: 12798577
[TBL] [Abstract][Full Text] [Related]
16. [What have we learned about inhibitors of the renin-angiotensin system?].
Waeber B; Nussberger J; Brunner HR
Ann Endocrinol (Paris); 1986; 47(3):167-77. PubMed ID: 3022638
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone system inhibitors in heart failure.
Shearer F; Lang CC; Struthers AD
Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
[TBL] [Abstract][Full Text] [Related]
18. Circulatory basis for the use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
Robertson JI
J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S2-8. PubMed ID: 2422488
[TBL] [Abstract][Full Text] [Related]
19. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934
[TBL] [Abstract][Full Text] [Related]
20. [Angiotensin-converting enzyme (ACE) inhibitors in cardiac decompensation; from randomized study to individual patient].
van Vlies B
Ned Tijdschr Geneeskd; 1992 Sep; 136(37):1796-8. PubMed ID: 1407135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
